KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    The Role of FOXO3 in Mechanisms of Doxorubicin Resistance in Hepatocellular Carcinoma

    Thumbnail
    View/Open
    Cox_ku_0099D_15101_DATA_1.pdf (3.287Mb)
    Issue Date
    2016-05-31
    Author
    Cox, Josiah
    Publisher
    University of Kansas
    Format
    106 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Microbiology, Molecular Genetics & Immunology
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Trans-arterial chemoembolization (TACE) with doxorubicin is commonly used to treat hepatocellular carcinoma (HCC), but has limited efficacy due to a high level of resistance. The factors that determine the sensitivity to TACE-doxorubicin are unknown. FOXO3 is a multifunctional transcription factor that plays a role in determining cell fate in response to stress. It frequently functions as a tumor suppressor but can also promote tumor pathogenesis. FOXO3 is also known to be a mediator of doxorubicin sensitivity in many types of tumor cells, while in others it can promote resistance. The role of FOXO3 in HCC and in doxorubicin resistance in HCC is unknown. FOXO3 function is largely determined by post-translational modification (PTM). Two FOXO3 PTMs, acetylation and serine 574 (S574)-phosphorylation, are known to promote its apoptotic function. Contrary to expectations, expression of FOXO3 was increased in HCC compared to surrounding liver. Cytosolic FOXO3 was significantly greater in TACE-resistant HCC as compared to treatment-naïve tumors. In Huh7 hepatoma cells, doxorubicin induced acetylation and S574-phosphorylation of FOXO3, and these modifications promoted doxorubicin-induced cell death by suppressing the pro-survival function of FOXO3. Resveratrol, an activator of SIRT deacetylase enzymes, inhibited these doxorubicin-induced PTMs and increased doxorubicin resistance. The expression of SIRT6, a known FOXO3 deacetylase, was also increased in TACE-resistant HCC tumors and correlated with cytosolic FOXO3. SIRT6 also blocked doxorubicin-induced S574-phosphorylation of FOXO3 and increased resistance to doxorubicin in Huh7 cells. Therefore, targeting SIRT6 and/or manipulating FOXO3 modifications may prove useful in enhancing the chemotherapy sensitivity of HCC.
    URI
    http://hdl.handle.net/1808/25878
    Collections
    • Dissertations [4454]
    • KU Med Center Dissertations and Theses [464]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    Login

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps